FFPE (formalin-fixed, paraffin-embedded) samples are a commonly used method in clinical practice for preserving pathological specimens, offering advantages such as long-term storage and rich clinical information. Therefore, extracting nucleic acids from FFPE samples is of great significance for applications in cancer research, the diagnosis of genetic diseases, and related fields. The Biokeystone NPure FFPE DNA/RNA Kit is designed to extract both DNA and RNA from a single sample. The kit requires no deparaffinisation step, contains no toxic or hazardous substances such as chloroform or phenol, and is compatible with a wide range of routine automated extraction instruments. The purified FFPE DNA and RNA products are of high quality, demonstrate consistency, and can be used directly in downstream applications.

Prenatal diagnosis refers to the examination and diagnosis of the developmental status of the embryo or fetus, as well as the presence of diseases, before birth. Prenatal diagnostic methods are generally divided into traumatic and non-invasive methods based on different sampling and examination methods. The former mainly includes amniocentesis, chorionic villus sampling, umbilical cord blood sampling, fetal endoscopy, and embryo biopsy. At present, traumatic methods are still the main method for prenatal diagnosis, with amniocentesis and chorionic villus sampling being the most commonly used. The Biokeystone NPure Blood DNA Extraction Kit (Cat.No.M2027) can be used to extract samples such as blood, amniotic fluid, villi, and cells, while the UPure Tissue DNA Kit (Cat.No.M2012) can be used to extract samples such as amniotic fluid, villi, and cells, providing assistance for prenatal diagnosis.

Hearing impairment is one of the common birth defects in humans. Screening for genetic variations in deafness in pregnant women and newborns can timely identify high-risk populations, provide prenatal intervention or guidance for the diagnosis and treatment of children, and is of great significance for the prevention and treatment of deafness. Neonatal deafness gene screening is the collection of umbilical cord or heel blood at birth or within 3 days after birth to screen for susceptibility and common genes of deafness. The Biokeystone UPure Swab DNA Kit (Cat.No.M2014) is suitable for extracting DNA from samples such as blood collection cards, saliva, and swabs, caring for the hearing health of babies.